Member Info for ChrisToffer

Whats up, doc?

Thought you got banned BYP? You're a pain the fuxking arse.

Hi B2, I assumed they would have been promoting those products at AACC.

The 30th Sep announcement was for CE marking of the products. The same process wouldn't apply in the US. In fact, I think Dean shared the FDA application numbers for both. They should have been able to promote them as RUOs though.

"Genome sequencing is so hot right now"

Come to think of it, would love to hear how SNPsig sales are performing.....

David, I believe the government would look to play the long game so as any business would feel obliged to make concessions/accept less than what they're contractually obliged to. The gov has all the time in the world where as businesses need to get paid.

Conversely, by taking the approach they have, NCYT have now written off the entire debacle and not recognised the revs. Theyre also showing that time is not a factor for them.

Unfortunately we suffer because of this stand off but if the company are contractually in the right, then they shouldn't give in to the government's despicable behaviour. After all, the call to arms came to British diagnostic came from them in the first place.

BYP, that doesn't add up;

Its for 129m (like it can't get any more as per the RNS) and, like you say, DHSC have outstanding invoices of around £73m.

2021 product was delivered and used - they even ordered more of the stuff last month.

Johnny Kipper, "Why would anyone enter into a major contract with NCYT now?"

Err, you mean like, the DHSC themselves? Who already have entered a £4m contract.

Fcuk there are some weapons on here today.

Talk of a raise is absolute nonsense.

Even if they had to fully refund the DHSC (which would have a repayment plan in it anyway), they would still have 20-30m cash at end of this year.

If they do a raise so they can buy a company -a very different proposition - that would add immediate revs to the group.

Kitzie, I have the same thought. Mullis' entire MO is targeted roll up M&A. Buying up companies and then selling the rolled up entity.

Conversely, David Allmond is not and M&A guy. He's all about product development a deal making.

As stressful as this is, I'm very interested to see where this goes in October and I'm deffo not selling until we find out.

Hi Kitzie, Yea that assumes a low ball, aggressive offer but the underlying business is delivering c.£40m EBIDTA.

EV/EBITDA ratios for the sector are 10-20 and we can then add an extra £1 a share to that for the cash position.

The company has stated 100m revenue guidance on several occasions now and that's a bare minimum.

Cut out all the noise and that should indicate this is undervalued. If someone came in with an offer now that caused an immediate rerate, the PIs who are selling can have no complaints because this company is a cash cow.

Avacta released interim results this morning. £10m loss.

https://www.businesswire.com/news/home/20210728006099/en/Novacyt-S.A.%C2%A0David-Allmond-Announced-as-CEO-Following-Decision-by-Graham-Mullis-to-Retire

David’s position on the board of Novacyt will be proposed for ratification by shareholders at the Company’s 2022 Annual General Meeting.

It was originally intended as a resolution for next years AGM. Strange timing indeed.

Yep. Same day DA starts.

Thanks B2, this was something I missed originally. I had always assumed it was either the M or S genes along with ORF1ab.

Reading the articles below gives me great confidence in the use of NSB16

Thanks Steve, you are correct.

It looks like the addition of NSP16 could well be from PROmate 2G.

From the first link i shared.

Coronaviruses employ between 20 and 30 proteins to carry out their viral replication cycle, including infection, immune evasion, and replication. Among these, nonstructural protein 16 (Nsp16), a 2'-O-methyltransferase, plays an essential role in immune evasion. Nsp16 achieves this by mimicking its human homolog, CMTr1, which methylates mRNA to enhance translation efficiency and distinguish self from other

Source for the below quote is here. https://www.activemotif.com/catalog/details/81318/recombinant-sars-cov-2-nsp16-protein

Would love to hear from some of our more learned posters on this.

SARS-CoV-2 NSP16 (Nonstructural Protein 16), also called as ribose 2'-O-methyltransferase, is one of the nonstructural proteins encoded by SARS-CoV-2 orf1ab. The polyproteins of CoVs are cleaved by virus-encoded cysteine proteinases comprise papain- and chymotrypsin-like proteases into 16 nonstructural proteins including the expression of NSP1 to NSP11 by orf1a and encoding NSP12 to NSP16 by orf1b. According to BLAST analysis, the sequence identity of ORF1ab protein between SARS-CoV-2 and SARS-CoV is more than 90% with the query cover of about 100%, while the sequence identity of NSP16 between these two viruses is about 93.24%

Looks like an assay thatll detection all coronaviruses?

Lools like a new assay. Bit of background on NSP16;

https://www.sciencedirect.com/science/article/pii/S000634952100254X